| HOME >> MEDICINE >> TECHNOLOGY |
—
—Common stock—par value $0.001; Authorized shares: 300,000,000, issued and
outstanding: 105,038,192 at December 31, 2010 and 102,746,058 at December 31, 2009
105,038
102,746Additional paid-in capital241,233,334
237,577,970Accumulated deficit(194,838,229)
(177,224,433)Accumulated other comprehensive income2,850
105,796Total Inovio Pharmaceuticals, Inc. stockholders' equity46,502,993
60,562,079Non-controlling interest597,918
622,868Total stockholders' equity47,100,911
61,184,947Total liabilities and stockholders' equity$56,067,391
$80,628,917Inovio Pharmaceuticals, Inc.CONSOLIDATED STATEMENTS OF OPERATIONSFor the Years ended December 31,201020092008Revenues:License fee and milestone revenue$213,916
$4,929,309
$791,401License fee and milestone revenue from affiliated entity313,306
18,222
—Revenue under collaborative research and development arrangements—
125,996
1,077,967Grants and miscellaneous revenue5,549,583
4,005,719
228,264Miscellaneous revenue from affiliated entity67,900
40,865
—Total revenues6,144,705
9,120,111
2,097,632Operating expenses:Research and development13,256,606
9,408,457
5,750,494General and administrative12,108,261
13,669,409
10,005,602Total operating expenses25,364,867
23,077,866
15,756,096Loss from operations(19,220,162)
(13,957,755)
(13,658,464)Other income (expense):Other income/(expense), net2,476,816
(1,258,848)
49,006Interest income, net74,514
2,293
643,836Loss from investment in affiliated entity(969,914)
(9,244,614)
—Net loss(17,638,746)
(24,
'/>"/>
| SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |